Ascorbic acid induces either differentiation or apoptosis in MG-63 osteosarcoma lineage

Anticancer Research

Volumn 34, Issue 4, 2014, Pages 1617-1628

  Valenti, Maria Teresa ^a,b   Zanatta, Mirko ^a,b   Donatelli, Luca ^a,b   Viviano, Gianmaria ^b   Cavallini, Chiara ^b   Scupoli, Maria Teresa ^b   Carbonare, Luca Dalle ^a,b  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

Author keywords

Apopotosis; Ascorbic acid; Differentiation; Osteoblast; Osteosarcoma

Indexed keywords

ALKALINE PHOSPHATASE; ANNEXIN; ASCORBIC ACID; BONE MORPHOGENETIC PROTEIN 2; CALCIUM; OSTEOCALCIN; OSTEOPONTIN; PROTEIN P21; TRANSCRIPTION FACTOR RUNX2; ANTINEOPLASTIC AGENT; ANTIOXIDANT; SPP1 PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BIOSYNTHESIS; BONE DEVELOPMENT; CELL DIFFERENTIATION; CELL MATURATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; NICK END LABELING; OSTEOBLAST; OSTEOSARCOMA CELL LINE; PHENOTYPE; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SPP1 GENE; APOPOTOSIS; BONE TUMOR; CELL LINEAGE; CELL SURVIVAL; DIFFERENTIATION; DOSE RESPONSE; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; OSTEOSARCOMA; PATHOLOGY; TUMOR CELL LINE;

APOPOTOSIS; ASCORBIC ACID; DIFFERENTIATION; OSTEOBLAST; OSTEOSARCOMA;

ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; APOPTOSIS; ASCORBIC ACID; BONE MORPHOGENETIC PROTEIN 2; BONE NEOPLASMS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL LINEAGE; CELL SURVIVAL; CORE BINDING FACTOR ALPHA 1 SUBUNIT; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; OSTEOPONTIN; OSTEOSARCOMA;

EID: 84902292433     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Bramwell VH: Osteosarcomas and other cancers of bone. Curr Opin Oncol 12: 330-336, 2000.
2. Haydon RC, Zhou L, Feng T, Breyer B, Cheng H, Jiang W, Ishikawa A, Peabody T, Montag A, Simon MA and He TC: Nuclear receptor agonists as potential differentiation therapy agents for human. osteosarcoma. Clin Cancer Res 8: 1288-1294, 2002.
3. Warrell RP Jr., de Thé H, Wang ZY and Degos L: Acute promyelocytic leukemia. N Engl J Med 329: 177-189, 1993.
4. Hata R: Regulation of gene expression and cell differentiation by ascorbic acid (vitamin C). In: Gene Expression and Nutrition. Muramatsu, T (ed.). Research Signpost, Trivandrum, pp. 53-72, 1996.
5. Arrigoni O and De Tullio MC: Ascorbic acid: Much more than just an antioxidant. Biochim Biophys Acta 1569: 1-9, 2002.
6. Langenbach F and Handschel JR: Effects of dexamethasone, ascorbic acid and β-glycerophosphate on the osteogenic differentiation of stem cells in vitro. Stem Cell Res Ther Sep 30;4(5): 117, 2013.
7. Prockop DJ and Kivirikko KK: Collagen: Molecular biology, diseases, and potential for therapy. Annu Rev Biochem 64: 403-434, 1995.
8. Duarte TL and Lunec J: When is an antioxidant not an antioxidant? A review of novel actions and reactions of vitamin C. Free Radic Res 39: 671-686, 2005.
9. Belin S, Kaya F, Duisit G, Giacometti S, Ciccolini J and Fontés M: Antiproliferative effects of ascorbic acid, is associated with the inhibition of genes necessary to cell cycle progression. PlosOne 4(2): e4409, 2009.
10. Sherr CJ: G1 Phase progression: Cycling on cue. Cell 79: 551-555, 1994.
11. Sherr CJ: Cancer cell cycles. Science 274: 1672-1677, 1996.
12. Hahm E, Jin DH, Kang JS, Kim YI, Hong SW, Lee SK, Kim HN, Jung da J, Kim JE, Shin DH, Hwang YI, Kim YS, Hur DY, Yang Y, Cho D, Lee MS and Lee WJ: Molecular mechanisms of vitamin C on cell cycle regulation in B16F10 murine melanoma. J Cell Biochem 102: 1002-1010, 2007.
13. Gibbs CP, Kukekov VG, Reith JD, Tchigrinova O, Suslov ON, Scott EW, Ghivizzani SC, Ignatova TN and Steindler DA: Stemlike cells in bone sarcomas: Implications for tumorigenesis. Neoplasia 7: 967-976, 2005.
14. Benayahu D, Shur I, Marom R, Meller I and Issakov J: Cellular and molecular properties associated with osteosarcoma cells. J Cell Biochem 84: 108-114, 2001.
15. Fletcher CDM and Unni KK: Pathology and genetics of tumours of soft tissue and bone. In: World Health Organization Classification of Tumours. Mertens F (ed.). IARC, Lyon, 2002.
16. 1-related antiproliferative function in osteoblasts. J Biol Chem 280: 20274-20285, 2005.
17. KIP1, is disrupted in osteosarcoma. J Cell Biol 167: 925-934, 2004.
18. Rosen CJ: The cellular and clinical parameters of anabolic therapy for osteoporosis. Crit Rev Eukaryot Gene Expr 13: 25-38, 2003.
19. Tashjian AH and Gagel RF: Teriparatide [human PTH(1-34)]: 2.5 years of experience on the use and safety of the drug for the treatment of osteoporosis. J Bone Miner Res 21: 354-365, 2006.
20. Bilezikian JP and Rubin MR: Combination/sequential therapies for anabolic and antiresorptive skeletal agents for osteoporosis. Curr Osteoporos Rep 4: 5-13, 2006.
21. Bendall AJ and Abate-Shen C: Roles for Msx and Dlx homeoproteins in vertebrate development. Gene 247: 17-31, 2000.
22. Johnsen IK, Kappler R, Auernhammer CJ and Beuschlein F: Bone morphogenetic proteins 2 and 5 are down-regulated in adrenocortical carcinoma and modulate adrenal cell proliferation and steroidogenesis. Cancer Res 69: 5784-5792, 2009.
23. von Bubnoff A and Cho KW: Intracellular BMP signaling regulation in vertebrates: Pathway or network? Dev Biol 239: 1-14, 2001.
24. 3 and ascorbic acid in bone derived cells. J Bone Miner Res 11: 1157-1167, 1990.
25. Takamizawa S, Maehata Y, Imai K, Senoo H, Sato S and Hata R: Effects of ascorbic acid and ascorbic acid 2-phosphate, a long acting vitamin C derivate, on the proliferation and differentiation of human osteoblast-like cells. Cell Biol Int 28: 255-265, 2004.
26. Heid CA, Stevens J, Livak KJ and Williams PM: Real-time quantitative PCR. Genome Res 6: 986-994, 1996.
27. Bruland OS and Pihl A: On the current management of osteosarcoma. A critical evaluation and a proposal for a modified treatment strategy. Eur J Cancer 33: 1725-1731, 1997.
28. Wu W, Zhang X and Zanello LP: 1α,25-Dihydroxyvitamin D(3) antiproliferative actions involve vitamin D receptor-mediated activation of MAPK pathways and AP-1/p21(WAF1) up-regulation in human osteosarcoma. Cancer Lett 254(1): 75-86, 2007.
29. Matsumoto T, Sowa Y, Ohtani-Fujita N, Tamaki T, Takenaka T, Kuribayashi K and Sakai T: p53-Independent induction of WAF1/Cip1 is correlated with osteoblastic differentiation by vitamin D3. Cancer Lett 129: 61-68, 1998.
30. Liu DD, Zhang JC, Zhang Q, Wang SX and Yang MS: TGF-β/BMP signaling pathway is involved in cerium-promoted osteogenic differentiation of mesenchymal stem cells. J Cell Biochem 114(5): 1105-1114, 2013.
31. Chen G, Deng C and Li YP: TGF-β and BMP signaling in osteoblast differentiation and bone formationInt. J Biol Sci 8(2): 272-288, 2012.
32. Lavery K, Hawley S, Swain P, Rooney R, Falb D and Alaoui-Ismaili MH: New insights into BMP-7 mediated osteoblastic differentiation of primary human mesenchymal stem cells. Bone 45(1): 27-41, 2009.
33. Wada Y, Kataoka H, Yokose S, Ishizuya T, Miyazono K, Gao YH, Shibasaki Y and Yamaguchi A: Changes in osteoblast phenotype during differentiation of enzymatically isolated rat calvaria cells. Bone 22(5): 479-485, 1998.
34. Kleeff J, Maruyama H, Ishiwata T, Sawhney H, Friess H, Büchler MW and Korc M: Bone morphogenetic protein 2 exerts diverse effects on cell growth in vitro and is expressed in human pancreatic cancer in vivo. Gastroenterology 116: 1202-1216, 1999.
35. Langenfeld EM, Calvano SE, Abou-Nukta F, Lowry SF, Amenta P and Langenfeld J: The mature bone morphogenetic protein-2 is aberrantly expressed in non-small cell lung carcinomas and stimulates tumor growth of A549 cells. Carcinogenesis 24: 1445-1454, 2003.
36. Ide H, Yoshida T, Matsumoto N, Aoki K, Osada Y, Sugimura T and Terada M: Growth regulation of human prostate cancer cells by bone morphogenetic protein-2. Cancer Res 57: 5022-5027, 1997.
37. Kawamura C, Kizaki M, Yamato K, Uchida H, Fukuchi Y, Hattori Y, Koseki T, Nishihara T and Ikeda Y. Bone morphogenetic protein-2 induces apoptosis in human myeloma cells with modulation of STAT3. Blood 96: 2005-2011, 2000.
38. Ghosh-Choudhury N, Woodruff K, Qi W, Celeste A and Abboud SL: Bone morphogenetic protein-2 blocks MDA MB 231 human breast cancer cell proliferation by inhibiting cyclin-dependent kinase-mediated retinoblastoma protein phosphorylation. Biochem Biophys Res Commun 272: 705-711, 2000.
39. Wen XZ, Miyake S, Akiyama Y and Yuasa Y: BMP-2 modulates the proliferation and differentiation of normal and cancerous gastric cells. Biochem Biophys Res Commun 316: 100-106, 2004.
40. Beck SE, Jung BH, Fiorino A, Gomez J and Rosario ED: Bone morphogenetic protein signaling and growth suppression in colon cancer. Am J Physiol Gastrointest Liver Physiol 291: G135-145, 2006.
41. Brubaker KD, Corey E, Brown LG and Vessella RL: Bone morphogenetic protein signaling in prostate cancer cell lines. J Cell Biochem 91: 151-160, 2004.
42. Wang L, Park P, Zhang H, La Marca F, Claeson A, Valdivia J and Lin CY: BMP-2 inhibits the tumorigenicity of cancer stem cells in human osteosarcoma OS99-1 cell line. Cancer Biol Ther 11: 457-463, 2011.
43. Franceschi RT: The developmental control of osteoblast specific gene expression: role of specific transcription factors and the extracellular matrix environment. Crit Rev Oral Biol Med 10: 40-57, 1999.
44. Xing W, Singgih A, Kapoor A, Alarcon CM, Baylink DJ and Mohan S: Nuclear factor-E2-related factor-1 mediates ascorbic acid induction of osterix expression via interaction with antioxidant-responsive element in bone cells. J Biol Chem 282(30): 22052-22061, 2007.
45. Maruyama Z, Yoshida CA, Furuichi T, Amizuka N, Ito M, Fukuyama R, Miyazaki T, Kitaura H, Nakamura K, Fujita T, Kanatani N, Moriishi T, Yamana K, Liu W, Kawaguchi H, Nakamura K and Komori T: RUNX2 determines bone maturity and turnover rate in postnatal bone development and is involved in bone loss in estrogen deficiency. Dev Dyn 236: 1876-1890, 2007.
46. Behrend EI, Craig AM, Wilson SM, Denhardt, DT and Chambers AF: Reduced malignancy of RAS-transformed NIH 3T3 cells expressing antisense osteopontin RNA. Cancer Res 54: 832-837, 1994.
47. Vuyyuri SB, Rinkinen J, Worden E, Shim H, Lee S and Davis KR: Ascorbic acid and a cytostatic inhibitor of glycolysis synergistically induce apoptosis in non-small cell lung cancer cells. PLoS One Jun 11;8(6): e67081, 2013.
48. Yan Liu, Xin Wang, Yuxin Xie, Jingui Zhang, Qingshan Wang and Xianhui Xu: Resveratrol induces apoptosis in human osteosarcoma MG63. Chin Journal of Clin Oncol 5: 361-366, 2008.
49. WAF1/CIP1 on apoptosis and sensitivity to cancer chemotherapy. Drug Resist Updates 6: 183-195, 2003.
50. Wu L, Yee A, Liu L, Carbonarohall D, Venkatesan N, Tolo V and Hall F: Early G1 induction of p21/WAF1/CIP1 in synchronized osteosarcoma cells is independent of p53. Oncol Rep 2: 227-231, 1995.
51. Wai PY and Kuo PC: Osteopontin: Regulation in tumor metastasis. Cancer Metastasis Rev 27: 103-118, 2008.